NasdaqGS:MYGN

Stock Analysis Report

Executive Summary

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Myriad Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.5%

MYGN

4.7%

US Biotechs

9.9%

US Market


1 Year Return

-57.7%

MYGN

-0.4%

US Biotechs

-11.9%

US Market

Return vs Industry: MYGN underperformed the US Biotechs industry which returned 0% over the past year.

Return vs Market: MYGN underperformed the US Market which returned -11.5% over the past year.


Shareholder returns

MYGNIndustryMarket
7 Day11.5%4.7%9.9%
30 Day-20.2%-6.7%-15.0%
90 Day-47.0%-8.6%-21.5%
1 Year-57.7%-57.7%0.4%-0.4%-10.0%-11.9%
3 Year-26.8%-26.8%9.3%6.6%12.3%5.1%
5 Year-59.9%-59.9%-6.4%-10.6%32.5%18.1%

Price Volatility Vs. Market

How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Myriad Genetics undervalued compared to its fair value and its price relative to the market?

5.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MYGN ($14.06) is trading below our estimate of fair value ($14.86)

Significantly Below Fair Value: MYGN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: MYGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MYGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYGN is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Myriad Genetics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

13.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MYGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MYGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MYGN's revenue (2.2% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: MYGN's revenue (2.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (5.1%).


Next Steps

Past Performance

How has Myriad Genetics performed over the past 5 years?

-27.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYGN is currently unprofitable.

Growing Profit Margin: MYGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of -27.3% per year.

Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: MYGN has a negative Return on Equity (-2.44%), as it is currently unprofitable.


Next Steps

Financial Health

How is Myriad Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: MYGN's short term assets ($365.3M) exceed its short term liabilities ($112.4M).

Long Term Liabilities: MYGN's short term assets ($365.3M) do not cover its long term liabilities ($388.6M).


Debt to Equity History and Analysis

Debt Level: MYGN's debt to equity ratio (20.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MYGN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: MYGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: MYGN's debt is covered by short term assets (assets are 1.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYGN has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: MYGN has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is Myriad Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

R. Riggsbee (48yo)

0.083

Tenure

US$3,138,983

Compensation

Mr. R. Bryan Riggsbee serves as an Interim President & Chief Executive Officer of Myriad Genetics, Inc. since February 6, 2020. He had been the Chief Financial Officer and Treasurer of Myriad Genetics Inc. ...


CEO Compensation Analysis

Compensation vs Market: R.'s total compensation ($USD3.14M) is about average for companies of similar size in the US market ($USD3.12M).

Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
R. Riggsbee
Interim President0.083yrUS$3.14m0.085% $893.9k
Alexander Ford
Chief Operating Officer0.17yrUS$3.23m0.083% $869.0k
Jerry Lanchbury
Chief Scientific Officer10yrsUS$2.69m0.16% $1.7m
Scott Gleason
Vice President of Investor Relationsno datano datano data
Benjamin Jackson
Executive VP0.67yrno data0.075% $787.3k
Clivetty Martinez
Chief Compliance Officer1.17yrsno datano data
Ronald Rogers
Executive Vice President of Corporate Communicationsno datano datano data
Jayne Hart
Executive Vice President of Human Resources8.83yrsno datano data
Gary King
Executive Vice President of International Operations9.67yrsno data0.11% $1.1m
Bernard Tobin
President of Myriad Autoimmune5.17yrsUS$2.73m0.093% $975.5k

3.2yrs

Average Tenure

54.5yo

Average Age

Experienced Management: MYGN's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lawrence Best
Independent Director10.5yrsUS$380.49k0.066% $690.4k
Walter Gilbert
Independent Vice Chairmanno dataUS$369.99k0.057% $597.0k
John Henderson
Independent Director15.83yrsUS$482.49k0.089% $933.6k
Dennis Langer
Independent Director15.83yrsUS$392.49k0.050% $526.1k
Lee Newcomer
Independent Director0.50yrno datano data
Colleen Reitan
Independent Director0.50yrno datano data
Heinrich Dreismann
Independent Director9.75yrsUS$384.99k0.058% $606.1k
S. Phanstiel
Independent Chair of the Boardno dataUS$399.49k0.045% $469.8k

10.1yrs

Average Tenure

66.5yo

Average Age

Experienced Board: MYGN's board of directors are seasoned and experienced ( 10.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MYGN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.


Top Shareholders

Company Information

Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Myriad Genetics, Inc.
  • Ticker: MYGN
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.048b
  • Shares outstanding: 74.55m
  • Website: https://myriad.com

Number of Employees


Location

  • Myriad Genetics, Inc.
  • 320 Wakara Way
  • Salt Lake City
  • Utah
  • 84108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1995
MYDDB (Deutsche Boerse AG)YesCommon StockDEEUROct 1995
MYDXTRA (XETRA Trading Platform)YesCommon StockDEEUROct 1995
0K3WLSE (London Stock Exchange)YesCommon StockGBUSDOct 1995

Biography

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 02:22
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.